Cellectar Biosciences (CLRB) Financials

Cellectar Biosciences (NASDAQ: CLRB) continues to look like a clinical-stage biotech with no product revenue and a heavy cash burn profile. The latest quarter showed zero revenue, a Q1 2026 net loss of $5.6 million, and negative operating cash flow of $4.8 million. Compared with the prior year, losses have improved from the much larger deficits seen in 2024, but the company is still not generating operating profits and remains dependent on financing.

One of the more important positives is that cash and equivalents were $8.3 million at March 31, 2026, up from $641,744 at the end of Q4 2025. That increase was driven largely by financing activity, not by operations, so it improves near-term liquidity but does not change the underlying business model. Shareholders’ equity also improved from the prior quarter, though the balance sheet still reflects a business that has used significant external capital over time.

• Cash improved materially in Q1 2026, ending the quarter at $8.3 million versus $0.6 million in Q4 2025.
• Operating losses are smaller than last year, with Q1 2026 net loss of $5.6 million versus $6.6 million in Q1 2025 and far less than Q1 2024’s $26.6 million loss.
• Operating cash burn has improved year over year, as Q1 2026 operating cash outflow of $4.8 million was better than Q1 2025’s $9.4 million.
• Other income helped offset some operating losses, with $140,000 of net other income in Q1 2026.
• The company remains pre-revenue, so progress is still tied to clinical and financing execution rather than commercial sales.
• Quarterly operating expenses remain elevated, with R&D of $3.0 million and SG&A of $2.8 million in Q1 2026.
• Share count has been volatile, suggesting repeated capital raises and/or structure changes that can complicate per-share metrics.
• Cash burn is still significant, and the current cash balance would not support many quarters of similar operating outflows without additional financing.
• Accounts payable and current liabilities remain high, with total current liabilities of $4.9 million against just $9.3 million in current assets.
• Long-term profitability is not yet visible, as the company has posted losses in every quarter shown across the last four years.

Looking at the broader trend, CLRB’s quarterly losses have generally narrowed from the extreme levels seen in 2024, when operating expenses and other charges were much larger. However, the company still burns cash every quarter and relies on financing to stay funded. The balance sheet also shows a history of dilution and capital structure complexity, including redeemable noncontrolling interests and large swings in equity accounts.

Bottom line: Cellectar Biosciences has made some progress on reducing losses and stabilizing liquidity, but the business is still in a high-risk, cash-consuming stage. For retail investors, the key question remains whether future clinical milestones can eventually justify the ongoing burn rate and financing needs.